Literature DB >> 11584691

The controversial early history of cyclosporin.

K Heusler1, A Pletscher.   

Abstract

The biological effects of cyclosporin, namely immunosuppression and absence of cytotoxicity, were discovered-in the course of a general screening program in which many scientists at Sandoz were involved. Contrary to some statements in the literature both Dr J. Borel and Dr H. Stähelin markedly contributed to the discovery and characterisation of the biological profile of the drug. In its subsequent exploitation Borel played the leading role. The outstanding clinical importance and the extraordinary commercial success of cyclosporin explain the widespread interest in the history of its discovery and development. It is also understandable that the recollection of the events by the individuals involved in the early phases of this history is influenced by subjective impressions and interpretations, which do not always reflect the historical facts. It is the purpose of this report to record and interpret the facts as accurately and as completely as possible on the basis of the available records.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11584691     DOI: 2001/21/smw-09702

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  8 in total

Review 1.  Natural product discovery: past, present, and future.

Authors:  Leonard Katz; Richard H Baltz
Journal:  J Ind Microbiol Biotechnol       Date:  2016-01-06       Impact factor: 3.346

Review 2.  Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs.

Authors:  Mitchell K P Lai; Wee Siong Chew; Federico Torta; Angad Rao; Greg L Harris; Jerold Chun; Deron R Herr
Journal:  Neuromolecular Med       Date:  2016-07-08       Impact factor: 3.843

3.  Expanding the limits of isonitrile-mediated amidations: on the remarkable stereosubtleties of macrolactam formation from synthetic seco-cyclosporins.

Authors:  Xiangyang Wu; Jennifer L Stockdill; Peter K Park; Samuel J Danishefsky
Journal:  J Am Chem Soc       Date:  2012-01-17       Impact factor: 15.419

Review 4.  Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents.

Authors:  Jinhe Han; Myoung Kyu Lee; Yejin Jang; Won-Jea Cho; Meeheyin Kim
Journal:  Drug Discov Today       Date:  2022-05-21       Impact factor: 8.369

Review 5.  Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications.

Authors:  Camila Flores; Guillemette Fouquet; Ivan Cruz Moura; Thiago Trovati Maciel; Olivier Hermine
Journal:  Front Immunol       Date:  2019-03-28       Impact factor: 7.561

6.  Proteomic Characterization of Urinary Extracellular Vesicles from Kidney-Transplanted Patients Treated with Calcineurin Inhibitors.

Authors:  Laura Carreras-Planella; Javier Juega; Omar Taco; Laura Cañas; Marcella Franquesa; Ricardo Lauzurica; Francesc Enric Borràs
Journal:  Int J Mol Sci       Date:  2020-10-14       Impact factor: 5.923

Review 7.  Peptidylprolyl Isomerases as In Vivo Carriers for Drugs That Target Various Intracellular Entities.

Authors:  Andrzej Galat
Journal:  Biomolecules       Date:  2017-09-29

8.  TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions.

Authors:  Nitin H Shirole; Debjani Pal; Edward R Kastenhuber; Serif Senturk; Joseph Boroda; Paola Pisterzi; Madison Miller; Gustavo Munoz; Marko Anderluh; Marc Ladanyi; Scott W Lowe; Raffaella Sordella
Journal:  Elife       Date:  2016-10-19       Impact factor: 8.140

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.